Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
169.6 USD | +0.07% | -0.30% | -14.09% |
May. 29 | Transcript : Zoetis Inc. Presents at Stifel Jaws & Paws Conference, May-29-2024 12:05 PM | |
May. 23 | Declaration of Voting Results by Zoetis Inc | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- With an expected P/E ratio at 30.96 and 28.08 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- Over the past four months, analysts' average price target has been revised downwards significantly.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-14.09% | 77.37B | B+ | ||
+18.66% | 8.74B | B- | ||
+23.75% | 3.67B | B- | ||
-0.42% | 3.25B | B- | ||
+18.07% | 1.73B | - | ||
-16.99% | 1.38B | B | ||
-0.39% | 1.31B | - | ||
-26.05% | 1.24B | C- | ||
-17.86% | 1.07B | - | ||
-6.77% | 976M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ZTS Stock
- Ratings Zoetis Inc.